Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW4421 Food Effect Study in Healthy Volunteers
NCT07364838Phase 1Completed
- Sponsor
- Daewon Pharm
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DW4421-1 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Daewon Pharm. Primary endpoints: Peak Plasma Concentration at 48 hours and Area under the plasma concentration versus time curve at 48 hours. Started Nov 2024; status: completed.
02
Drugs
DW4421-1
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07364838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364838.